Gilead (GILD) Issues Strong '7977 Update, Shares Move Higher

February 3, 2012 10:03 AM EST Send to a Friend
Shares of Gilead Sciences, Inc. (Nasdaq: GILD) are moving higher Friday following positive data related to its experimental hepatitis C (HCV) treatments.

On the company's fourth-quarter earnings conference call late Thursday, Gilead's scientific chief Norbert Bischofberger said trials of PSI-7977 in patients with genotype 1 HCV showed no signs of the virus after being on the drug for four weeks.

PSI-7977 was said to cure patients with genotypes 2 and 3, according to earlier studies.

Competitors in the field include Merck (NYSE: MRK), Vertex Pharma (NYSE: VRTX), Bristol-Myers Squibb (NYSE: BMY), Idenix Pharma (Nasdaq: IDIX) and Achillion Pharma (Nasdaq: ACHN).

A number of analysts issued comments on Gilead following the call. For more color, click here.

Gilead shares last traded at $54.40, up 10.3 percent from Thursday's close.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Insiders' Blog

Related Entities

Earnings

Add Your Comment